Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

BACKGROUND: Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Med Oncol
Autors principals: Ono, Atsushi, Aikata, Hiroshi, Yamauchi, Masami, Kodama, Kenichiro, Ohishi, Waka, Kishi, Takeshi, Ohya, Kazuki, Teraoka, Yuji, Osawa, Mitsutaka, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Abe-Chayama, Hiromi, Zhang, Peiyi, Liu, Songyao, Makokha, Grace Naswa, Tsuge, Masataka, Imamura, Michio, Hayes, C. Nelson, Chayama, Kazuaki
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Early Diagnosis and Therapeutic Advances for Liver Cancer: From Bench to Bedside
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7249573/
https://ncbi.nlm.nih.gov/pubmed/32547646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920922051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars